dc.contributor.author | Arpa, Muhammet Davut | |
dc.contributor.author | Üstündağ Okur, Neslihan | |
dc.contributor.author | Gök, Mehmet Koray | |
dc.contributor.author | Özgümüş, Saadet | |
dc.contributor.author | Cevher, Erdal | |
dc.date.accessioned | 2023-07-21T07:14:16Z | |
dc.date.available | 2023-07-21T07:14:16Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Arpa, M. D., Üstündağ Okur, N., Gök, M. K., Özgümüş, S. ve Cevher, E. (2023). Chitosan-based buccal mucoadhesive patches to enhance the systemic bioavailability of tizanidine. International Journal of Pharmaceutics, 642. https://dx.doi.org/10.1016/j.ijpharm.2023.123168 | en_US |
dc.identifier.issn | 0378-5173 | |
dc.identifier.issn | 1873-3476 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.ijpharm.2023.123168 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/11233 | |
dc.description.abstract | Tizanidine hydrochloride (TZN) is a muscle relaxant used to treat a variety of disorders such as painful muscle spasms and chronic spasticity. TZN has low oral bioavailability due to extensive first-pass metabolism and is used orally at a dose of 6–24 mg per day. In the present study, buccal patches were prepared by solvent casting method using chitosan glutamate (Chi-Glu) and novel chitosan azelate (Chi-Aze) which was synthesised in-house for the first time, to enhance the bioavailability of TZN by bypassing first-pass metabolism. The characterisation, mucoadhesion and drug release studies were performed. Chi-Aze patches retained their integrity longer in the buccal medium and showed higher ex vivo drug permeability compared to that prepared with Chi-Glu. In vivo studies revealed that buccal formulation fabricated with Chi-Aze (3%) showed approx 3 times more bioavailability than the orally administered commercial product. Results of the studies indicate that Chi-Aze, prepared by conjugation of chitosan and a fatty acid, the patch formulation is a promising buccal mucoadhesive system due to the physical stability in buccal medium, the good mucoadhesiveness and the high TZN bioavailability. Moreover, Chi-Aze patch might be an alternative to oral formulations of TZN to reduce the dose and frequency of drug administration. | en_US |
dc.description.sponsorship | Primex EHF | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier B.V. | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Azelaic Acid | en_US |
dc.subject | Bioavailability | en_US |
dc.subject | Buccal Patch | en_US |
dc.subject | Chitosan | en_US |
dc.subject | Mucoadhesion | en_US |
dc.subject | Tizanidine | en_US |
dc.title | Chitosan-based buccal mucoadhesive patches to enhance the systemic bioavailability of tizanidine | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Journal of Pharmaceutics | en_US |
dc.department | İstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Farmasötik Teknoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9290-2404 | en_US |
dc.identifier.volume | 642 | en_US |
dc.relation.tubitak | info:eu-repo/grantAgreement/TUBITAK/SOBAG/217S257 | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.ijpharm.2023.123168 | en_US |
dc.institutionauthor | Arpa, Muhammet Davut | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001024632000001 | en_US |
dc.identifier.scopus | 2-s2.0-85163418157 | en_US |
dc.identifier.pmid | 37356512 | en_US |
dc.identifier.scopusquality | Q1 | en_US |